printemailclick to share buttonfacebooktwitterlinkedin
Hematology Cancer Evidence-based Series (EBS) and Practice Guidelines (PG)

Hematology cancers include blood and lymphatic system disorders.

The Hematology Cancer Disease Site Group (Hematology DSG) produces evidence-based reports to assist practitioner and patient decisions about appropriate health care for specific clinical circumstances.  The titles of the reports produced to date by the DSG are listed below, with links to the PDF versions of those reports.  

The PEBC has a formal standardized process to ensure the currency of each document. This process guides clinical experts to assess a document’s current status and relevance (please see the PEBC Assessment & Review Protocol for more information). A final status statement is added to the document when this review process is complete. The current status of each guidance document is noted beside the title and link as outlined below:

  • Documents listed as CURRENT are 3 years old or less, up-to-date, and can be used for decision making.
  • Documents listed as IN REVIEW are undergoing assessment for currency and relevance.  The DSG/GDG has determined that it is still appropriate for this document to continue to be available while this updating process unfolds.
  • Documents that are listed as “FOR EDUCATION AND INFORMATION PURPOSES” are documents for which no further updates are planned and whose recommendations may no longer be consistent with recent evidence.  They may be of educational, historical, clinical, or system interest.

If you have any questions regarding a document that is “In Review,” please contact the PEBC ( ) or the lead author of the document.

  • Systemic Therapy in Acute Lymphoblastic Leukemia
    12-16 ES: June 2016
    Status: CURRENT
  • Systemic Treatment of Acute Myeloid Leukemia (AML)
    Guideline 12-9: February 2016
    Status: CURRENT
  • Management of Early-Stage Hodgkin Lymphoma
    Guideline 6-20: December 2015
    Status: CURRENT
  • Rituximab in Lymphoma and Chronic Lymphocytic Leukemia: A Clinical Practice Guideline
    Guideline 6-8 Version 3: March 2015
    Status: CURRENT
  • Bortezomib in Multiple Myeloma and Lymphoma
    6-18 EBS Version 2: March 2013 Requires Updating
    Status: IN REVIEW
  • Lenalidomide in Multiple Myeloma
    6-5 Version 2 EBS: September 2015
    Status: CURRENT

For Education and Information Purposes

  • Optimal Therapy for Patients Diagnosed with Multiple Myeloma and the Role of High-Dose Chemotherapy and Stem Cell Support
  • The Use of Chemotherapy and Growth Factors in Older Patients with Newly Diagnosed, Advanced-Stage, Aggressive Histology Non-Hodgkin's Lymphoma
  • Alemtuzumab in Chronic Lymphocytic Leukemia
  • The Role of Bisphosphonates in the Management of Skeletal Complications for Patients with Multiple Myeloma
  • Treatment with Fludarabine for Patients with Follicular and other Low Grade Non-Hodgkin's Lymphoma and Waldenstrom's Macroglobulinemia
  • Thalidomide in Multiple Myeloma: Guideline Recommendations
  • Treatment of Chronic Myeloid Leukemia with Imatinib
  • Treatment of Anemia with Erythropoietic Agents in Patients with Cancer – Adaption/Adoption of ASH-ASCO Guidelines
    • Available on Request
  • Treatment of Acute Myeloid Leukemia in Older Patients
  • Ibritumomab Tiuxetan in Lymphoma
  • Iodine-131 Tositumomab in Lymphoma
  • The Management of Malignant Thrombocytosis in Philadelphia Chromosome-Negative Myeloproliferative Disease
  • Fludarabine in Intermediate- and High-Risk Chronic Lymphocytic Leukemia
    6-1 PG
    This guideline is available upon request at 
  • Drug Therapy for Chronic Myeloid Leukemia
    6-3 PG
    This guideline is available upon request at . Current treatment recommendations for chronic myeloid leukemia are reflected in EBS 6-15 Treatment of Chronic Myeloid Leukemia with Imatinib.
Program in Evidence-Based Care (PEBC)
McMaster University, Juravinski Site
G Wing, 2nd Floor
711 Concession Street
Hamilton, Ontario, Canada
L8V 1C3

Phone: 905.527.4322 ext. 42822
Fax: 905.526.6775
Last modified: Fri, Jun 23, 2017
cancer care ontario | action cancer ontario   620 University Avenue Toronto Ontario, Canada M5G 2L7   Phone: 416.971.9800 Fax: 416.971.6888

Please help improve the quality of our website by answering 10 brief questions in our online survey. Would you like to participate?